학술논문
32O 5-year (y) overall survival (OS) with maintenance olaparib (ola) plus bevacizumab (bev) by clinical risk in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) in the phase III PAOLA-1/ENGOT-ov25 trial
Document Type
Abstract
Author
Lorusso, D.; Mouret-Reynier, M-A.; Harter, P.; Cropet, C.; Caballero Diaz, C.; Petru, E.; Satoh, T.; Vergote, I.B.; Parma, G.; Jakobi Nøttrup, T.; Lebreton, C.; Fasching, P.A.; Pisano, C.; Manso, L.; Bourgeois, H.; Runnebaum, I.; Hardy-Bessard, A-C.; Schnelzer, A.; Pujade-Lauraine, E.; Ray-Coquard, I.L.
Source
In ESMO Open February 2023 8(1) Supplement 1
Subject
Language
ISSN
2059-7029